Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: A 13-week, randomized, placebo-controlled trial

Pain is a common cause of disability in osteoarthritis. Duloxetine, a serotonin and norepinephrine reuptake inhibitor (SNRI), has demonstrated analgesic effects in diabetic peripheral neuropathy and fibromyalgia. Considering its central mechanism of action, duloxetine may be effective in other pain states with evidence of central sensitization. This article reports the results of a 13-week, randomized, double-blind, placebo-controlled trial of duloxetine (60–120 mg/day) versus placebo in the treatment of knee pain in 231 patients meeting clinical and radiographic criteria for osteoarthritis of the knee. Duloxetine was superior to placebo on the primary efficacy measure (weekly mean 24-h pain scores) beginning at Week 1 and continuing through the treatment period (P less-than-or-equals, slant .05). There was also a significant improvement in the WOMAC physical functioning subscale and several other secondary outcomes. Adverse-event rates did not differ significantly between treatment groups (49.5% for duloxetine 60–120 mg/day, and 40.8% for placebo).

Duloxetine, a centrally acting analgesic, is more effective than placebo in the treatment knee pain due to osteoarthritis.

Amy S. Chappell, Melissa J. Ossanna, Hong Liu-Seifert, Smriti Iyengar, Vladimir Skljarevski, Linda Chunhong Li, Robert M. Bennett and Harry Collins. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: A 13-week, randomized, placebo-controlled trial. Pain, Volume 146, Issue 3, 5 December 2009, Pages 253-260

Knee Assessment and Hip Mechanics

Learn how how faulty hip and pelvis mechanics influence knee function under load with this short online course.

Speak your mind

Your email will not be published.